Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
China
Biotech
Zephyrm seeks Hong Kong IPO to fund phase 3 cell therapy trials
Zephyrm filed for an IPO to bankroll phase 3 trials of its cell therapy in a lung condition and graft-versus-host disease.
Nick Paul Taylor
Oct 2, 2024 8:19am
2 cancer biotechs merge, creating global footprint
Sep 25, 2024 10:54am
Connect reduces China workforce, mulls strategy for asthma drug
Sep 6, 2024 4:37am
Allist pays Jacobio $21M, landing role in Chinese KRAS race
Aug 30, 2024 9:12am
YolTech sells China rights to gene editing therapy for $29M
Aug 27, 2024 10:24am
Merck pays $700M for bispecific challenger to Amgen cancer drug
Aug 9, 2024 8:52am